Roche Has “Reasonable” Chance Of Launching Its Long-Acting EPO In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche believes is has a "reasonable" chance of being able to launch its long-acting EPO product CERA in the U.S. upon approval despite expected patent challenges, the company said Sept. 13 at the Bear Stearns health care conference in New York.
You may also be interested in...
Roche Continuous Epoetin CERA BLA Submitted For Dosing Every Four Weeks
CERA will have an estimated user fee date of mid February under standard review for treatment of renal anemia.
Roche Continuous Epoetin CERA BLA Submitted For Dosing Every Four Weeks
CERA will have an estimated user fee date of mid February under standard review for treatment of renal anemia.
Roche Gearing For CERA Renal Anemia BLA In 2006
Roche readies CERA long-acting anti-anemia therapy BLA for 2006 filing. Four Phase III trials meet primary endpoint of hemoglobin maintenance.